ViiV Healthcare announces positive new data for Apretude use during pregnancy at AIDS 2024

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today shared new maternal safety and pregnancy outcomes and pharmacokinetic (PK) findings from the HIV Prevention Trials Network (HPTN) 084 open label extension (OLE) evaluating cis-gender women in sub-Saharan Africa who became pregnant while using Apretude (cabotegravir LA for PrEP) for HIV pre-exposure prophylaxis (PrEP). The findings showed that cabotegravir LA for PrEP was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period.^1,2 These data will be presented at the 25th International AIDS Conference being held in Munich, Germany (22 – 26 July).

Additional information to the following link: ViiV Healthcare announces positive new data for Apretude use during pregnancy at AIDS 2024 | GSK